Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Atherosclerotic Cardiovascular Disease (ASCVD): later-stage trial registry
3 of 5 indexed Atherosclerotic Cardiovascular Disease (ASCVD) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Atherosclerotic Cardiovascular Disease (ASCVD): 5 US clinical trials tracked, 3 recruiting.
Atherosclerotic Cardiovascular Disease (ASCVD) is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 3 of these trials.
Enrollment posture brief
Registry condition atherosclerotic-cardiovascular-disease-ascvd
OPEN 3 | RECR 60% | LATE 4 | EARLY 0 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Atherosclerotic Cardiovascular Disease (ASCVD) lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Atherosclerotic Cardiovascular Disease (ASCVD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Atherosclerotic Cardiovascular Disease (ASCVD) is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Atherosclerotic Cardiovascular Disease (ASCVD) research.
Eli Lilly and Company accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical Atherosclerotic Cardiovascular Disease (ASCVD) enrolment sits around 10,000 participants.
Median target enrolment is 10,000 among the 5 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.
-
Atherosclerotic Cardiovascular Disease (ASCVD) research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Eli Lilly and Company
NCT07157774
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Novartis Pharmaceuticals
NCT06813911
The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study
Brigham and Women's Hospital
NCT07315997
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company
NCT06292013
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company
NCT06383390
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Atherosclerotic Cardiovascular Disease (ASCVD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Atherosclerotic Cardiovascular Disease (ASCVD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Atherosclerotic Cardiovascular Disease (ASCVD) page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Atherosclerotic Cardiovascular Disease (ASCVD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Atherosclerotic Cardiovascular Disease (ASCVD) trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atherosclerotic Cardiovascular Disease (ASCVD) condition card totals 5 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.